Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698544 | 0.95 | KMT2A (0.47) | KMT2AMEN1HPGDNPSR1ALDH1A1 | |
| SCHEMBL2962259 | 0.91 | ALDH1A1 (0.43) | KMT2AMEN1HPGDNPSR1ALDH1A1 | |
| SCHEMBL12102445 | 0.91 | KMT2A (0.42) | KMT2AMEN1HPGDNPSR1ALDH1A1 | |
| SCHEMBL13338203 | 0.90 | KMT2A (0.43) | KMT2AMEN1HPGDNPSR1ALDH1A1 | |
| SCHEMBL3688111 | 0.88 | KMT2A (0.45) | KMT2AMEN1HPGDNPSR1ALDH1A1 | |
| SCHEMBL12102442 | 0.87 | KMT2A (0.39) | KMT2AMEN1HPGDNPSR1ALDH1A1 | |
| SCHEMBL5676195 | 0.86 | KMT2A (0.37) | KMT2AMEN1HPGDNPSR1ALDH1A1 | |
| SCHEMBL5676198 | 0.86 | KMT2A (0.37) | KMT2AMEN1HPGDNPSR1ALDH1A1 | |
| SCHEMBL13202982 | 0.86 | ALDH1A1 (0.39) | KMT2AMEN1HPGDNPSR1ALDH1A1 | |
| SCHEMBL3692467 | 0.86 | KMT2A (0.43) | KMT2AMEN1HPGDNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | HDAC5, HDAC7, HDAC4 | KMT2A 226/4885MEN1 2082/4885HPGD 80/4885 |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | CD74, HLA-DRB1, HDAC5 | KMT2A 311/4885MEN1 1809/4885HPGD 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.